These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 21103911)

  • 21. Drug evaluation: Deferitrin for iron overload disorders.
    Barton JC
    IDrugs; 2007 Jul; 10(7):480-90. PubMed ID: 17642018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The origin of the differences in (R)- and (S)-desmethyldesferrithiocin. Iron-clearing properties.
    Bergeron RJ; Wiegand J; Ratliff-Thompson K; Weimar WR
    Ann N Y Acad Sci; 1998 Jun; 850():202-16. PubMed ID: 9668541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Desazadesmethyldesferrithiocin analogues as orally effective iron chelators.
    Bergeron RJ; Wiegand J; Weimar WR; Vinson JR; Bussenius J; Yao GW; McManis JS
    J Med Chem; 1999 Jan; 42(1):95-108. PubMed ID: 9888836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Desferrithiocin: a search for clinically effective iron chelators.
    Bergeron RJ; Wiegand J; McManis JS; Bharti N
    J Med Chem; 2014 Nov; 57(22):9259-91. PubMed ID: 25207964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical and clinical development of deferitrin, a novel, orally available iron chelator.
    Donovan JM; Plone M; Dagher R; Bree M; Marquis J
    Ann N Y Acad Sci; 2005; 1054():492-4. PubMed ID: 16339704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Scaffold Based Search on the Desferithiocin Archetype.
    Shyam M; Dev A; Sinha BN; Jayaprakash V
    Mini Rev Med Chem; 2019; 19(19):1564-1576. PubMed ID: 30827237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The design of orally active iron chelators.
    Hider RC; Zhou T
    Ann N Y Acad Sci; 2005; 1054():141-54. PubMed ID: 16339660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators.
    Bergeron RJ; Wiegand J; Dionis JB; Egli-Karmakka M; Frei J; Huxley-Tencer A; Peter HH
    J Med Chem; 1991 Jul; 34(7):2072-8. PubMed ID: 2066978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolically programmed iron chelators.
    Bergeron RJ; Bharti N; McManis JS; Wiegand J
    Bioorg Med Chem; 2015 Sep; 23(17):5954-71. PubMed ID: 26231739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug evaluation: deferitrin (GT-56-252; NaHBED) for iron overload disorders.
    Barton JC
    IDrugs; 2007 Apr; 10(4):270-81. PubMed ID: 17390251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The desferrithiocin (DFT) class of iron chelators: potential as antineoplastic agents.
    Kicic A; Chua AC; Baker E
    Anticancer Drug Des; 2001; 16(4-5):195-207. PubMed ID: 12049478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A non-human primate model for the study of oral iron chelators.
    Wolfe LC; Nicolosi RJ; Renaud MM; Finger J; Hegsted M; Peter H; Nathan DG
    Br J Haematol; 1989 Jul; 72(3):456-61. PubMed ID: 2765410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemia.
    Taher AT; Saliba AN; Kuo KH; Giardina PJ; Cohen AR; Neufeld EJ; Aydinok Y; Kwiatkowski JL; Jeglinski BI; Pietropaolo K; Berk G; Viprakasit V
    Am J Hematol; 2017 Dec; 92(12):1356-1361. PubMed ID: 28940308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of iron chelator efficacy in iron-overloaded beagle dogs and monkeys (Cebus apella).
    Bergeron RJ; Wiegand J; Weimar WR; Lindstrom TC; Fannin TL; Ratliff-Thompson K
    Comp Med; 2004 Dec; 54(6):664-72. PubMed ID: 15679265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of desferrithiocin and its derivatives on peripheral iron and striatal dopamine and 5-hydroxytryptamine metabolism in the ferrocene-loaded rat.
    Dexter DT; Ward RJ; Florence A; Jenner P; Crichton RR
    Biochem Pharmacol; 1999 Jul; 58(1):151-5. PubMed ID: 10403528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and biological evaluation of naphthyldesferrithiocin iron chelators.
    Bergeron RJ; Wiegand J; Wollenweber M; McManis JS; Algee SE; Ratliff-Thompson K
    J Med Chem; 1996 Apr; 39(8):1575-81. PubMed ID: 8648596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The desferrithiocin pharmacophore.
    Bergeron RJ; Liu CZ; McManis JS; Xia MX; Algee SE; Wiegand J
    J Med Chem; 1994 May; 37(10):1411-7. PubMed ID: 8182699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The hexadentate hydroxypyridinonate TREN-(Me-3,2-HOPO) is a more orally active iron chelator than its bidentate analogue.
    Yokel RA; Fredenburg AM; Durbin PW; Xu J; Rayens MK; Raymond KN
    J Pharm Sci; 2000 Apr; 89(4):545-55. PubMed ID: 10737916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparative evaluation of iron clearance models.
    Bergeron RJ; Streiff RR; Wiegand J; Vinson JR; Luchetta G; Evans KM; Peter H; Jenny HB
    Ann N Y Acad Sci; 1990; 612():378-93. PubMed ID: 2127168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.
    Hershko C; Konijn AM; Nick HP; Breuer W; Cabantchik ZI; Link G
    Blood; 2001 Feb; 97(4):1115-22. PubMed ID: 11159545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.